There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors. The company could soon face biosimilar competition from one of its key growth drivers, Eylea, while it recently received an important regulatory approval from the U.S. Food and Drug Administration (FDA). With that said, let's dig deeper into what's happening with Regeneron and figure out whether it is worth investing in the drugmaker.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles